Personalized Therapy for Cancer

  • Kewal K. JainEmail author


Management of cancer has been unsatisfactory in the past but an understanding of the molecular, genetic and genomic aspects of cancer started to accelerate progress in cancer therapy (Jain 2005). Several comprehensive studies have demonstrated the utility of gene expression profiles for the classification of tumors into clinically relevant subtypes and the prediction of clinical outcomes. The role of oncoproteomics in the personalized management of cancer was first emphasized in 2004 (Jain 2004). Considerable progress has been made in this field during the past few years. Other factors that drive the development of personalized therapy for cancer are listed in Table 10.1. The preceding chapter described how cancer cell therapy and cancer vaccines can be personalized. Information presented in this chapter describes personalization of other cancer therapies.


Breast Cancer Epidermal Growth Factor Receptor Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Cancer Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Acharya CR, Hsu DS, Anders CK et al (2008) Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299:1574–1587PubMedGoogle Scholar
  2. Agadjanian H, Ma J, Rentsendorj A et al (2009) Tumor detection and elimination by a targeted gallium corrole. Proc Natl Acad Sci USA 106:6105–6110PubMedGoogle Scholar
  3. Alvero AB, Chen R, Fu HH et al (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8:158–166PubMedGoogle Scholar
  4. Anderson AR, Weaver AM, Cummings PT, Quaranta V (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127:905–915PubMedGoogle Scholar
  5. Antoch G, Kanja J, Bauer S et al (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357–365PubMedGoogle Scholar
  6. Beier D, Röhrl S, Pillai DR et al (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68:5706–5715PubMedGoogle Scholar
  7. Ben-Haim S, Ell P (2009) 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 50:88–99PubMedGoogle Scholar
  8. Bild AH, Yao G, Chang JT et al (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353–357PubMedGoogle Scholar
  9. Bosco EE, Wang Y, Xu H et al (2007) The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 117:218–228PubMedGoogle Scholar
  10. Boyer J, Allen WL, McLean EG et al (2006) Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66:2765–2777Google Scholar
  11. Brower SL, Fensterer JE, Bush JE (2008) The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol 414:57–78PubMedGoogle Scholar
  12. Burgess DJ, Doles J, Zender L et al (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 105:9053–9058PubMedGoogle Scholar
  13. Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192PubMedGoogle Scholar
  14. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedGoogle Scholar
  15. Carrasco DR, Tonon G, Huang Y et al (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313–325PubMedGoogle Scholar
  16. Carter SL, Eklund AC, Kohane IS et al (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38:1043–1048PubMedGoogle Scholar
  17. Chaurand P, Sanders ME, Jensen RA, Caprioli RM (2004) Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 165:1057–1068PubMedGoogle Scholar
  18. Chen HY, Yu SL, Chen CH et al (2007) A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer. NEJM 356:11–20Google Scholar
  19. Cunningham L, Aplenc R (2007) Pharmacogenetics of acute lymphoblastic leukemia treatment response. Expert Opin Pharmacother 8:2519–2531PubMedGoogle Scholar
  20. de la Iglesia N, Konopka G, Puram SV et al (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22:449–462PubMedGoogle Scholar
  21. Diehn M, Nardini C, Wang DS et al (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci USA 105: 5213–5218PubMedGoogle Scholar
  22. El-Deiry WS, Sigman CC, Kelloff GJ (2006) Imaging and oncologic drug development. J Clin Oncol 24:3261–3273PubMedGoogle Scholar
  23. Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–1388PubMedGoogle Scholar
  24. Endo K, Sasaki H, Yano M et al (2006) Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep 16:533–541PubMedGoogle Scholar
  25. Fogli S, Caraglia M (2009) Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives. Expert Opin Pharmacother 10:1095–1108PubMedGoogle Scholar
  26. Freedman AN, Slattery ML, Ballard-Barbash R et al (2009) A colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 27:686–693.Google Scholar
  27. Fry RJ, Svensson JP, Valiathan C et al (2008) Genomic predictors of interindividual differences in response to DNA damaging agents. Genes Dev 22:2621–2626PubMedGoogle Scholar
  28. Garman KS, Acharya CR, Edelman E et al (2008) A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 105:19431–19437Google Scholar
  29. Giotopoulos G, Symonds RP, Foweraker K et al (2007) The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 96:1001–1007PubMedGoogle Scholar
  30. Glas AM, Floore A, Delahaye LJ et al (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7(1):278.PubMedGoogle Scholar
  31. Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318PubMedGoogle Scholar
  32. Gong Y, Yan K, Lin F et al (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8:203–211PubMedGoogle Scholar
  33. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedGoogle Scholar
  34. Hirsch FR, Witta S (2005) Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 17:118–122PubMedGoogle Scholar
  35. Holdenrieder S, Stieber P, von Pawel J et al (2004) Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 10:5981–5987.PubMedGoogle Scholar
  36. Huang RS, Duan S, Bleibel WK et al (2007) A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 104:9758–9763PubMedGoogle Scholar
  37. Idbaih A, Marie Y, Pierron G et al (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483–487PubMedGoogle Scholar
  38. Inoges S, Rodriguez-Calvillo M, Zabalegui N et al (2006) Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98:1292–1301PubMedGoogle Scholar
  39. Iwadate Y, Sakaida T, Saegusa T et al (2005) Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int J Oncol 26:993–998PubMedGoogle Scholar
  40. Jain KK (2004) Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics 1:49–55PubMedGoogle Scholar
  41. Jain KK (2005) Personalised medicine for cancer – from drug development into clinical practice. Exp Opin Pharmacother 6:1463–1476Google Scholar
  42. Jain KK (2009k) Molecular diagnosis of brain tumors. In: Gilman S (ed) Medlink neurology, Medlink Corporation, San Diego, CA.Google Scholar
  43. Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S et al (2005) Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther 12:699–707PubMedGoogle Scholar
  44. Jeuken JWM, van der Maazen RWM, Wesseling P (2006) Molecular diagnostics as a tool to personalize treatment in adult glioma patients. Technol Cancer Res Treat 5:215–229PubMedGoogle Scholar
  45. Juhász C, Muzik O, Lu X et al (2009) Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med 50:356–363PubMedGoogle Scholar
  46. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765PubMedGoogle Scholar
  47. Kimura H, Kasahara K, Kawaishi M et al (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915–3921Google Scholar
  48. Korpanty G, Carbon JG, Grayburn PA et al (2007) Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 13:323–330PubMedGoogle Scholar
  49. Kretschmar C, Kleinberg L, Greenberg M et al (2007) Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 48:285–291PubMedGoogle Scholar
  50. Labuhn M, Vuaroqueaux V, Fina F et al (2006) Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int J Biol Markers 21:30–39PubMedGoogle Scholar
  51. Laing RE, Walter MA, Campbell DO et al (2009) Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci USA 106:2847–2852PubMedGoogle Scholar
  52. Lapointe J, Li C, Higgins JP et al (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811–816PubMedGoogle Scholar
  53. Leary RJ, Lin JC, Cummins J et al (2008) Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 105:16224–16229PubMedGoogle Scholar
  54. Lee E, Nichols P, Spicer D et al (2006) GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 66:7849–7853PubMedGoogle Scholar
  55. Leong C, Vidnovic N, DeYoung MP et al (2007) The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117:1370–1380PubMedGoogle Scholar
  56. Liang Y, Diehn M, Watson N et al (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 102:5814–5819PubMedGoogle Scholar
  57. Liu R, Wang X, Chen GY et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217–226PubMedGoogle Scholar
  58. Lorenzi PL, Reinhold WC, Rudelius M et al (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 5:2613–2623PubMedGoogle Scholar
  59. Lukes L, Crawford N, Walker R, Hunter KW (2009) The origins of breast cancer prognostic gene expression profiles. Cancer Res 69:310–318PubMedGoogle Scholar
  60. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedGoogle Scholar
  61. Ma XJ, Hilsenbeck SG, Wang W et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611–4619PubMedGoogle Scholar
  62. Maheswaran S, Sequist LV, Nagrath S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366–377PubMedGoogle Scholar
  63. Mandl SJ, Mari C, Edinger M et al (2004) Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 3:1–8Google Scholar
  64. Mannello F, Medda V, Tonti GA (2009) Protein profile ana lysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev Proteomics 6:43–60PubMedGoogle Scholar
  65. Marcuello E, Altes A, Menoyo A et al (2006) Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 57:835–840PubMedGoogle Scholar
  66. Martinez R, Schackert G, Esteller M (2007) Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol 82:133–139PubMedGoogle Scholar
  67. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024PubMedGoogle Scholar
  68. Miller LD, Liu ET (2007) Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res 9:206.PubMedGoogle Scholar
  69. Moffat BA, Chenevert TL, Lawrence TS et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102:5524–5529PubMedGoogle Scholar
  70. Moreton P, Kennedy B, Lucas G et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971–2979PubMedGoogle Scholar
  71. Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286PubMedGoogle Scholar
  72. Mukohara T, Engelman JA, Hanna NH et al (2005) Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185–1194PubMedGoogle Scholar
  73. Nagrath S, Sequist LV, Maheswaran S et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450:1235–1239PubMedGoogle Scholar
  74. Nuyten DS, Kreike B, Hart AA et al (2006) Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62.PubMedGoogle Scholar
  75. Ogino S, Nosho K, Kirkner GJ et al (2008) A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 100:1734–1738PubMedGoogle Scholar
  76. Ornish D, Magbanua M, Weidner G et al (2008) Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci USA 105:8369–8374PubMedGoogle Scholar
  77. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedGoogle Scholar
  78. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedGoogle Scholar
  79. Park S, Hatanpaa KJ, Xie Y et al (2009b) The receptor interacting protein 1 inhibits p53 induction through NF-{kappa}B activation and confers a worse prognosis in glioblastoma. Cancer Res 69:2809–2816Google Scholar
  80. Park Y, Freedman AN, Gail MH et al (2009a) Validation of a colorectal cancer risk prediction model among whites 50 years old and over. J Clin Oncol 27:694–698Google Scholar
  81. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167PubMedGoogle Scholar
  82. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812PubMedGoogle Scholar
  83. Petty RD, Kerr KM, Murray GI et al (2006) Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol 24:1729–1744PubMedGoogle Scholar
  84. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedGoogle Scholar
  85. Polo JM, Juszczynski P, Monti S et al (2007) Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 104:3207–3212PubMedGoogle Scholar
  86. Potti A, Dressman HK, Bild A (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12:1294–1300PubMedGoogle Scholar
  87. Pritchard KI, Shepherd LE, O’Malley FP et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103–2111PubMedGoogle Scholar
  88. Rieger KE, Hong WJ, Tusher VJ et al (2004) Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage. Proc Natl Acad Sci USA 101:6635–6640PubMedGoogle Scholar
  89. Rosell R, Cuello M, Cecere F et al (2006) Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol 18:135–143PubMedGoogle Scholar
  90. Rottenberg S, Jaspers JE, Kersbergen A et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079–17084PubMedGoogle Scholar
  91. Rouzier R, Rajan R, Wagner P et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315–8320PubMedGoogle Scholar
  92. Santana VM, Furman WL, Billups CA et al (2005) Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23:4039–4047PubMedGoogle Scholar
  93. Schmieder AH, Winter PM, Caruthers SD et al (2005) Molecular MR imaging of melanoma angiogenesis with anb3-targeted paramagnetic nanoparticles. Magnet Reson Med 53:621–627Google Scholar
  94. Schwartz SA, Weil RJ, Thompson RC et al (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65:7674–7681PubMedGoogle Scholar
  95. Sequist LV, Nagrath S, Toner M et al (2009) The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 4:281–283PubMedGoogle Scholar
  96. Serkova N, Boros LG (2005) Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. Am J Pharmacogenomics 5:293–302PubMedGoogle Scholar
  97. Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274PubMedGoogle Scholar
  98. Sohn JW, Lee SY, Lee SJ et al (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137–141PubMedGoogle Scholar
  99. Song LL, Miele L (2007) Cancer stem cells--an old idea that’s new again: implications for the diagnosis and treatment of breast cancer. Expert Opin Biol Ther 7:431–438Google Scholar
  100. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMedGoogle Scholar
  101. Stamatakos GS, Antipas VP, Uzunoglu NK (2006) Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. Comput Biol Med 36:1216–1234PubMedGoogle Scholar
  102. Stanulla M, Schaeffeler E, Flohr T et al (2005) Thiopurine methyltransferase (tpmt) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293:1485–1489PubMedGoogle Scholar
  103. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 103:11154–11159PubMedGoogle Scholar
  104. Taguchi F, Solomon B, Gregorc V et al (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99:838–846PubMedGoogle Scholar
  105. Teschendorff AE, Miremadi A, Pinder SE et al (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8:R157PubMedGoogle Scholar
  106. Thomas G, Horvath S, Smith BL et al (2004) Antibody based profiling of the PI3K pathway in clinical prostate cancer. Clin Cancer Res 10:8351–8356PubMedGoogle Scholar
  107. Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133–144PubMedGoogle Scholar
  108. Visintin I, Feng Z, Longton G et al (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14:1065–1072PubMedGoogle Scholar
  109. Wang W, Kim SH, El-Deiry WS (2006) Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. PNAS 103:11003–11008Google Scholar
  110. Watters JW, Kraja A, Meucci MA et al (2004) Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 101:11809–11814PubMedGoogle Scholar
  111. Weber WA, Petersen V, Schmidt B et al (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657PubMedGoogle Scholar
  112. Weichselbaum RR, Ishwaran H, Yoon T et al (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 105:18490–18495PubMedGoogle Scholar
  113. Weinstein JN (2006) Spotlight on molecular profiling: “integromic” analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 5:2601–2605PubMedGoogle Scholar
  114. Wu X, Lu C, Chiang SS, Ajani JA (2005) Pharmacogenetics in esophageal cancer. Semin Oncol 32(6 Suppl 9):87–89Google Scholar
  115. Xing D, Orsulic S (2005) A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci USA 102: 6936–6941PubMedGoogle Scholar
  116. Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017–1021Google Scholar
  117. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808PubMedGoogle Scholar
  118. Zhu H, Acquaviva J, Ramachandran P et al (2009) Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA 106:2712–2716PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations